AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING)

Summary

This is a Phase 2, open-label, single-arm study of neoadjuvant immune-checkpoint blockade therapy (AK104) combining with TACE for resectable hepatocellular carcinoma. The purpose is to investigate the efficacy and safety of this therapeutic regimen to reduce the risk of postoperative recurrence in resectable HCC patients with a high risk of recurrence.

Timeline

Start

2023-01-01

Primary completion

2025-01-01

Completion

2025-01-01

Drugs

Indications